![]() |
首页 > 美迪医讯 > 报告:慢性肾脏疾病在美国 |
报告:慢性肾脏疾病在美国 【 2008-10-10 发布 】 美迪医讯
公众健康中心一个重要的发现是那些慢性肾脏疾病患者更倾向于因心脏血管疾病死亡而非因为晚期肾脏疾病。这个结果建议那些从慢性肾脏疾病到晚期肾脏疾病的转变过程值得引起注意,并指出在这项研究的开始的这个月,慢性到晚期肾脏疾病这个转变期间范围医疗保险病人需要支付14,500美元,商业医疗保险计划病人需要支付29,000美元,这个问题非常值得思考。
Report: Chronic Kidney Disease in the US
A 30 percent increase in chronic kidney disease over the past decade has prompted a report documenting the disease. It affects an estimated 27 million Americans and accounts for more than 24 percent of Medicare costs.
Using data from multiple sources, the U.S. Renal Data System (USRDS) has created a new handbook of information that can be used by researchers, government officials, health programme planners, and others to develop research goals, assess public health needs, set programme priorities, and inform policymakers and the public.
One of the major findings central to public health is that those with chronic kidney disease are more likely to die from cardiovascular disease than to reach end-stage kidney disease. However, cardiovascular risk factors can be detected and treated. This suggests that those transitioning from chronic to end-stage kidney disease merit more attention. Expenditures during the transition from chronic to end-stage kidney disease are considerable, ranging from 14,500 U.S. dollars for Medicare patients to 29,000 U.S. dollars for those covered by employer group health plans in the month of dialysis initiation. The report shows that the number of people with end-stage kidney disease is increasing in size and cost. The incidence of chronic kidney disease in 2006 was more than 100,000, or 360 per one million people, an increase of 3.4 percent over the 2005 incidence rate. There were more than half a million patients with end-stage kidney disease in 2006. Of these, 70 percent were on dialysis. Medicare paid about 70,000 U.S. dollars per dialysis patient, so the report. Patients with end-stage kidney disease accounted for a little more than one percent of the Medicare population and more than seven percent of Medicare costs. Total cost for end-stage kidney disease was 33.6 billion U.S dollars. This number includes Medicare spending and all expenditures by other payers, such as employer group health plans. In addition, more than 18,000 kidney transplants were performed in 2006, an increase of 3.5 percent over 2005. Use of deceased donor kidneys increased between 2003 and 2006 at a rate of about six percent to seven percent. Use of living donors fell three percent during that period, but the use of living unrelated donors continues to increase relative to the total number of living donations, and now accounts for 45 percent of all living donor transplantations. 本文关键字:
《美迪医讯》欢迎您参与新闻投稿,业务咨询: 美迪医疗网业务咨询《上海医疗器械批发》产品推荐
|
合作支持:中华医学会 | 中华医院管理学会 | 国家食品药品监督管理家用护理器械商城 | 国药励展展览有限责任公 | 医学装备协会 |
刊登广告 | 友情链接 | 广告代理商加盟 | 关于美迪 | 法律声明 | 隐私保护 | 网站地图 |
把美迪网放进收藏夹 把美迪医疗网介绍给我的朋友 给美迪医疗网留言
美迪医疗网广告业务联系:021-51601230 产品咨询业务联系:021-51601230 传真:021-56532303 ![]() 互联网药品信息服务许可证:(沪)-经营性-2009-0003 中华人民共和国电信与信息服务业务经营许可证:(沪)B2-20090029 ![]() ![]() ![]() 公安备案号 31010602000199 医疗器械经营许可证: 沪静药监械经营许20210003号 第二类医疗器械经营备案凭证: 沪静药监械经营备20220042号 营业执照:统一社会信用代码91310108676284138X互联网药品信息服务资格书:(沪)-非经营性-2023-0081 |